Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | TSPO | P30536 | 1/20 | 0.81 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.74 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.74 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.74 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.74 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.74 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.74 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.74 |
| ▸ | GABRP | O00591 | 2/20 | 0.74 |
| ▸ | GABRD | O14764 | 2/20 | 0.74 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.74 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.74 |
| ▸ | GABRE | P78334 | 2/20 | 0.74 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.74 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.74 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.74 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.74 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268100 | 0.91 | LMNA (0.67) | LMNAGAATSPOGABRA1GABRA5 | |
| Ro-54864 SCHEMBL29754019 | 0.90 | LMNA (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Ro-54864 SCHEMBL60200 | 0.90 | LMNA (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL29244910 | 0.86 | LMNA (0.63) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL30327558 | 0.86 | LMNA (0.63) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL11631556 | 0.85 | LMNA (0.85) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL9472656 | 0.85 | LMNA (0.85) | LMNAGAATSPOGABRA1GABRA5 | |
| SCHEMBL30327572 | 0.85 | LMNA (0.62) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL21442 | 0.85 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 | |
| Diazepam SCHEMBL1019217 | 0.85 | GABRA1 (1.00) | LMNAGAATSPOGABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4898861-A | ADMINISTERING BENZODIAZEPINE COMPOUNDS, SELECTIVE AFFINITY FOR BINDING SITES ON CELL | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | claimed |
| EP-2217576-B1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | UNIV MICHIGAN (US) | 2016-05-11 | — | — | EP | disclosed |
| US-8759340-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-17 | — | — | US | disclosed |
| US-8461153-B2 | Benzodiazepinone compounds useful in the treatment of skin conditions | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2139331-B1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | UNIV MICHIGAN (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2139331-B1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | UNIV MICHIGAN (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242109-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-14 | — | — | US | disclosed |
| US-7851465-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851465-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2139331-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | The Regents of the University of Michigan (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112553-A1 | COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-09-18 | — | — | WO | disclosed |
| US-4898861-A | ADMINISTERING BENZODIAZEPINE COMPOUNDS, SELECTIVE AFFINITY FOR BINDING SITES ON CELL | HOFFMANN-LA ROCHE INC. (US) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269194-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | LMNA 2006/4885GAA 2662/4885TSPO 86/4885 |
| US-20090118244-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | LMNA 2002/4885GAA 2723/4885TSPO 554/4885 |
| US-20130274197-A1 | BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS | RORC, RORA, RORB | LMNA 2002/4885GAA 2723/4885TSPO 554/4885 |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | LMNA 2006/4885GAA 2662/4885TSPO 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.